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Background: With an increasing life expectancy and improved treatment regimens for primary or secondary
malignant diseases of soft tissue or bone, hemipelvectomy will have to be considered more often in elderly
patients in the future. Scientific reviews concerned with the surgical and oncological outcome of elderly patients
undergoing hemipelvectomy are scarce. Therefore, it is the purpose of this study to review the outcome of patients
treated with that procedure at our hospital and investigate the feasibility of such extensive procedures at an
increased age.
Methods: A retrospective analysis of thirty-four patients who underwent hemipelvectomy at an age of 65 years or
older was performed to determine their surgical and oncological outcome. The Kaplan-Meier method was used to
calculate the cumulative probability of survival using the day of tumor resection as a starting point. Univariate
analysis was carried out to investigate the influence of a particular single parameter.
Results: The mean age at operation was 70.2 years. Thirty patients were treated for intermediate- to high-grade
sarcoma and 81.8% of tumors were larger than or equal to 10 cm in the longest diameter. Thirteen patients
underwent internal hemipelvectomy and nine patients external hemipelvectomy as a primary procedure. Twelve
patients were treated with external hemipelvectomy after failed local tumor control at primary operation. Wound
infection occurred in 61.7% of cases. Three patients underwent amputation for non-manageable infection after
internal hemipelvectomy. Hospital mortality was 8.8%. Clear resection margins were obtained in 88% of patients;
in another 6% of patients planned intralesional resections were performed. Local recurrence occurred in 8.8% of
patients at a mean time of 26 months after operation. Eleven patients are alive with no evidence of disease and 23
patients died of disease or other causes. Patients with pulmonary metastases had a mean survival period after
operation to DOD of 22 months compared to 37 months in the curative group.
Conclusion: Despite an elevated rate in hospital mortality and wound infection, this study suggests that
hemipelvectomy is feasible in elderly patients, although requiring long hospitalization periods and causing a limited
functional outcome.
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Pelvic surgery is an accepted treatment for primary ma-
lignant tumors of soft tissue and bone. Depending on
tumor size, site, proximity to neurovascular structures
and abdominal organs as well as the stage of disease, the
indication for carrying out an internal or external hemi-
pelvectomy has to be evaluated.
Internal hemipelvectomy is a surgical procedure of
partial to complete unilateral resection of bone and soft
tissue of the pelvis with preservation of the adjacent leg,
whereas in external hemipelvectomy - also referred to
as hindquarter amputation - the adjacent leg is resected
as well. Internal hemipelvectomy is indicated when
tumor resection with wide margins can be obtained
without sacrificing the neurovascular structures and the
remaining tissue (muscle, subcutaneous tissue and skin)
is acceptable to perform a functional reconstruction.
External hemipelvectomy is indicated when the neuro-
vascular structures are compromised by tumor growth,
as well as in recurrent tumors when clear surgical
margins can only be obtained by performing ablative
procedures.
The overall prognosis of pelvic tumors is still inferior
compared to the results achieved in extremity surgery
for different tumor entities [1-3]. Complications after
operations occur frequently, including genitourinary
and gastrointestinal injuries, mass bleeding, infection or
vascular occlusion [4,5].
A review of recent literature reveals that hemipelvec-
tomies are performed in all age groups with predomin-
ance in younger patients with a mean or median age
ranging between 17.9 and 60 years [3,6,7]. The number
of patients treated with a hemipelvectomy above the age
of 65 years per study is small and Ham et al. show that
performing the procedure in older patients has not al-
ways been deemed feasible in the past [8,9].
But due to an improvement of oncological therapies,
internal and external hemipelvectomy also come into
focus as a means of treating metastatic disease in
addition to soft tissue and bone sarcomas of the pelvis
[6,10]. Therefore, the feasibility of hemipelvectomy in
older patients with comorbidities as an aggravating fac-
tor will need to be assessed more frequently in the
future.
With an increasing significance of major pelvic sur-
gery as a treatment option for elderly patients and a lack
of existing studies on this subgroup’s overall outcome,
we retrospectively evaluated the surgical and onco-
logical outcome in patients above the age of sixty-five
years who have been treated with hemipelvectomy at
our department from 1999 until 2012. Therefore, the
aim of this study is to analyze whether these patients
benefit from hemipelvectomy in terms of surgical safety
and oncological follow-up.Methods
Patient eligibility
Records of patients who underwent internal and external
hemipelvectomy at our department between 1999 and
2012 were retrospectively reviewed.
Thirty-four patients who were sixty-five years of age or
older at the time of operation and underwent hemipelvect-
omy for primary bone or soft tissue sarcomas, bony me-
tastases or benign bony lesions in the pelvic region were
considered eligible for the analysis. Patients were followed
up quarterly in our outpatient clinic for the first two years
after operation. Magnetic resonance imaging (MRI) and x-
rays of the pelvis were performed for local follow-up.
Computed tomography (CT) scans and x-rays of the chest
were obtained biannually, each procedure once per year.
Until completion of the fifth year after surgery biannual
follow-ups were scheduled. Patients, family members,
attending physicians and the local residents’ registration
office were contacted for information on the current state
of disease when patients didn’t follow up in our outpatient
clinic as recommended.
Diagnostic staging
Conventional x-rays and magnetic resonance imaging
were mandatory for depiction of the pelvic tumor prior to
operation. A CT of the chest and a 99-Tc-methylene
diphosphonate bone scan were also required. The stage of
disease at the time of operation was defined according to
the system of the Musculoskeletal Tumor Society [11].
Pelvic resections were classified using the system of
Enneking and Dunham [12]. Measurement of the largest
tumor diameter was performed on the MR images or
taken from histopathological reports, sorting them into
three groups (small: ≤ 10cm, intermediate: ≥ 10 cm, large:
≥ 20cm).
Except for selected cases, operation aimed at a complete
removal of the tumor with wide or radical margins. Surgi-
cal and histopathological reports were used to define the
margins according to Enneking [13]. Local failure was de-
fined as development of a local recurrence or tumor pro-
gression after intralesional operation.
Patient characteristics
Out of thirty-four patients, twenty patients were male
(59%) and fourteen patients female (41%). The mean age at
operation was 70.2 years (range 65 – 83 years). The mean
body mass index (BMI) was 26.2 (range 20.8 – 37.7). Severe
comorbidities were known in 47% of patients (i.e. cardio-
vascular disease, diabetes mellitus, stroke, second neoplastic
disease).
In twenty-three cases (68%) the tumor originated in
the bone; eleven cases (32%) of soft tissue sarcoma were
treated. Histological subtypes can be seen in Table 1. In two
cases a dedifferentiation of low-grade chondrosarcoma in
Table 1 Frequency distribution of diagnosis and grading in patients treated with hemipelvectomy
Diagnosis Bone tumor Soft tissue tumor
Grading Benign Regressive Low-grade
(G1)
Intermediate-grade
(G2)
High-grade
(G3)
Total Intermediate-grade
(G2)
High-grade
(G3)
Total
Chondrosarcoma 2 9 7 18
Pleomorphic sarcoma 1 1 1 6 7
Leiomyosarcoma 2 1 3
Osteosarcoma 2 2
Fibrosarcoma 1 1
Metastasis thyroid
cancer
1 1
Giant cell tumor 1 1
Total 1 1 2 9 10 23 3 8 11
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mass was located in the ilium in thirteen cases (38.2%), the
proximal thigh in seven cases (20.6%), the acetabulum in five
cases (14.7%), the gluteal region in four cases (11.8%), the
proximal femur in three cases (8.8%) and the ischiopubic
bone and inguinal region in one case (2.9%) each. The lar-
gest tumor diameter was ≤ 10 cm in 18.2% of cases (n = 6),
≥ 10 cm in 54.5% of cases (n = 18) and ≥ 20 cm in 27.3% of
cases (n = 9). In one patient, information on tumor size was
not available. The stage of disease was as follows in decreas-
ing order: IIB (high-grade extracompartimental) n = 19, IIIB
(metastatic extracompartimental) n = 8, IB (low-grade extra-
compartimental) n = 4 and IIA (high-grade intracomparti-
mental) n = 1. In one case, a benign Stage III lesion (locally
aggressive) was found. In one case the staging system didn’t
apply (#31 in Tables 2 and 3). An overview of treated cases
can be seen in Tables 2 and 3. Twenty-five patients were
treated with a curative intent whereas hemipelvectomy was
carried out in nine patients with a palliative intention. A
curative intention was defined as the ability to achieve clear
surgical margins in patients who showed no metastases at
the time of operation.
Operation
A total of thirty-seven hemipelvectomies were performed
in thirty-four patients. Primary tumor resection was per-
formed in 59.4% of patients (n = 22) and secondary resec-
tions for recurrent (n = 5) or persistent (n = 7) tumor after
inadequate procedures in 32.4% of patients. Internal hemi-
pelvectomy was performed in thirteen patients. Three pa-
tients had intraarticular resections, seven patients had
extraarticular resections and three patients had supraace-
tabular resections. The subtypes can be seen in Table 2.
External hemipelvectomy was performed in twenty-one
patients including all patients who underwent surgery for
recurrent or persistent disease (n = 12; 32.4%). In three pa-
tients (8.8%) a conversion of internal to external hemipel-
vectomy was necessary due to otherwise non-manageable
infection.Nine patients received a hip transposition using an at-
tachment tube as a means of reconstruction. In seven pa-
tients (53.8%) who underwent extraarticular resections,
reconstruction was performed using a mega-prosthesis
(MUTARS® (Modular Universal Tumor And Revision Sys-
tem) proximal femur mega-prosthesis, implantcast, Buxte-
hude, Germany). Six out of seven mega-prostheses had a
silver coating. In three supraacetabular resections a recon-
struction of the pelvic girdle was achieved using a poly-
axial screw-rod system with a poly methyl methacrylate
(PMMA) coating. One patient did not receive a recon-
struction after a P3 resection with preservation of the hip
joint.
Oncology
In seven patients chemotherapy was administered.
Twelve patients received radiotherapy of the pelvis; in
six cases radiotherapy was performed before operation.
Functional outcome
Due to a small number of surviving patients and a small
number of patients included in this study, we did not per-
form functional outcome scores but used a descriptive
classification to present functional aptitude and limitations
of patients after the surgical procedure.
Statistics
The Kaplan-Meier method was used to calculate the cumu-
lative probability of survival using the day of operation as a
starting point. Univariate analysis was carried out to investi-
gate the influence of a particular single parameter.
Patient consent
Before the initiation of treatment, all patients included
in this study consented to the possibility of being in-
cluded in a study with a retrospective design in the fu-
ture and publication of their data in an anonymized
fashion.
Table 2 Overview of patient characteristics, surgical outcome
Case Age at
operation
Tumor
entity
Grading Tumor
site
Tumor
size (cm)
Tumor
stage
Operation
indication
Type of
procedure
Subtype of
procedure
Surgical
revision (n)
VAC duration
Y/N days
1 68 GCT benign ischiopubic 6x6x7 III (benign) PR int intra P3 N N
2 69 LMS 2 prox thigh 19 IIB SR LR ext P2/3 1 N
3† 71 CS 2 ilium >10 IIIB SR PI ext P1-4 N N
4 72 CS 2 prox thigh 43 IIIB PR EXULC ext P2/3 1 Y
5† 69 CS 3 ilium 22x18x16 IIB PR ext P1-4 3 Y 68
6 65 CS 2 ilium 10x13 IIB PR ext P1-4 0 N
7 69 CS 3 acetabular 6,5x10x12 IIB PR int extra* P1-4 11 Y 93
8 74 CS 3 ilium 20x11x14 IIIB PR int* P1c 2 N
9 72 CS 1 ilium 8x6x8 IB SR PI ext P1-4 N N
10 73 OS 3 prox femur 5 IIA PR int extra P2/3 2 Y 95
11 78 PS 3 prox thigh 31x17x15 IIB PR EXULC ext P2/3 0 N
12 67 CS 2 ilium 22x30 IIB PR int intra P1-4 5 Y 170
13 71 CS 2 ilium >20 IIB PR ext P1-4 N N
14† 76 PS 3 prox thigh 9x8x6 IIB SR PI ext P2/3 1 N
15 67 CS 2 ilium 10x10x10 IIB PR int extra P2/3 3 N
16 66 CS 3 acetabular 10x7x5 IIIB SR LR ext P1-4 N N
17 72 CS 3 acetabular 12 IIB PR int ext P2/3 N N
18 70 LMS 2 inguinal 19 IIB PR ext P1-4 1 N
19 67 OS 3 acetabular 8,8x11,8 IIB SR LR ext P1-4 3 Y 42
20 83 LMS 3 gluteal 16x8x5 IIB SR PI ext P1-4 1 Y
21 66 PS 3 gluteal 12x9 IIB PR ext P2/3 N N
22 69 CS 1 ilium 5x6x7 IB PR int extra P2-4 N N
23 66 CS 2 ilium 18 IIIB PR pall int intra P1-4 1 Y
24 70 FS 3 thigh 15x12x13 IIB SR PI ext P1-4 3 Y 14
25 72 PS 3 prox thigh NA IIB SR LR ext P2/3 N N
26 71 CS 2 acetabular 7x6x10 IIB PR int extra P1-4 1 N
27 70 PS 3 prox femur 20x13x12 IIIB SR PI ext P2/3 N N
28 65 CS 3 ilium 12x10x12 IIB PR ext P1-4 3 Y 14
29 69 PS 3 gluteal 24x14x19 IIB SR LR ext P2/3 N N
30 71 CS 3 prox femur 12x10x7 IIIB SR PI ext P1-4 0 N
31 65 TCMet regressive ilium 2x2x2 - PR int P1c N N
32 73 PS 3 prox thigh 30x12x13 IIIB PR ext P2/3 N N
33 75 PS 2 gluteal 10x10x6 IB PR int extra* P1-4 9 Y 10/61
34 65 CS 2 ilium 12x11x9 IB PR int P1cHSPCL5 3 Y 38
Abbreviations: † = death on hospital ward, GCT = giant cell tumor, LMS = leiomyosarcoma, CS = chondrosarcoma, OS = osteosarcoma, PS = pleomorphic sarcoma,
FS = fibrosarcoma, TCMet = thyroid cancer metastasis, prox = proximal, NA = not available, PR = primary resection, SR LR = secondary resection for local recurrence,
SR PI = secondary resection post intralesional operation, PR EXULC = primary resection of exulcerating tumor, PR pall = primary R1 resection in palliative situation,
int intra = internal intraarticular hemipelvectomy, ext = external hemipelvectomy, int extra = internal extraarticular hemipelvectomy, int = internal hemipelvectomy,
* = patients with second-stage external hemipelvectomy due to infection; P3 = ischiopubic region, P2/3 = ischiopubic and acetabular region, P1-4 = iliac, acetabular,
ischiopubic and massa lateralis region, P1c = iliac and massa lateralis region, P2-4 = acetabular, ischiopubic and massa lateralis region, P1cHSPCL5 = iliac,
hemisacrectomy and partial corporectomy of fifth lumbar vertebrae, N = No, Y = Yes.
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In Germany, a formal ethics approval is not deemed ne-
cessary due to the retrospective study design of this
study.Results
Duration of operation and blood loss
The mean duration of operation was 235.3 minutes
(range 95–455 minutes). For internal hemipelvectomy
Table 3 Overview of patient characteristics, oncological outcome
Case Metastasis at
operation
Margin Local recurr.
(months)
Distant metastasis
after first operation
(months)
Time to death
after distant
metastasis (months)
Cause of
death
Death at month after
last major operation
Alive at
month
Function
1 N 1 I N - - 60 CR
2 N 0 W 31 DOD 38 -
3† Y 0 NA N surg. 0 -
4 Y 0 R N DOD 1 -
5† N 0 W N 3 0 post surg. 2 -
6 N 0 W N - - 166 WC
7 N 0 W N 3,5 0 DOD 1 -
8 Y 0 W N DOD 24 -
9 N 0 R N DOD 1 -
10 N 0 R N 3 - - - 64 NA
11 N 0 R N DOD 40 -
12 N 0 W N - - 22 WC/CR
13 N 1 I N - - 80 WC/CR
14† N 0 R N post surg. 1 -
15 N 0 W N - - 87 WC/CR
16 Y 0 W N other 82 -
17 N 0 M N other 40 -
18 N 0 M N other 95 -
19 N 0 W N - - 38 WC/CR
20 N 0 W N DOD 7 -
21 N 0 W N NA 15 -
22 N 0 W N - - 57 NA
23 Y 1 I N DOD 12 -
24 N 0 M N DOD 7 -
25 N 0 W N NA 6 -
26 N 0 M N other 4 -
27 Y 0 M N DOD 9 -
28 N 1 I 11 11 8 DOD 18 -
29 N 0 W N 41 8,5 DOD 48 -
30 Y 0 W 35 DOD 48 -
31 Y 0 W N - - 19 WF
32 Y 0 R N DOD 3 -
33 N 0 W N - - 15 B/WC
34 N 0 W N - - 7 WC/CR
Abbreviations: † = death on hospital ward, Y = Yes, N = No, R = radical, W = wide, M =marginal, I = intralesional, DOD = Dead of Disease, surg. = surgery,
post surg. = post operation on ward, other = other cause of death, CR = crutches/cane, WC = wheelchair, WF = ambulating without walking aid, B = bed-ridden.
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with 302.2 minutes (range 179–455 minutes) compared to
189.6 minutes (range 95–400 minutes) in external hemi-
pelvectomy. Blood loss had to be substituted with a mean
of 10.2 erythrocyte concentrates (EC) (range 2 – 42 EC)
and a mean of 8.5 fresh frozen plasmas (FFP) (range 0–52
FFP). A mean blood substitution of 10 ECs (range 2 – 21EC) was necessary in internal and 10.5 ECs (range 3 – 42
EC) in external hemipelvectomy.
Length of Hospital Stay (LOHS)
The mean LOHS was 52 days (range 13–114 days) both
for internal and external hemipelvectomy. Separated for
internal and external hemipelvectomy the mean LOHS
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(range 15–91 days) for external hemipelvectomy respect-
ively. Patients who underwent a conversion from in-
ternal to external hemipelvectomy had a mean LOHS of
70 days (range 40–114 days).
The recommended bed rest during LOHS was a mean
of 15 days (range 3–70 days), with a mean of 29 days
(range 5–42 days) for internal and a mean of 6 days (range
3–14 days) for external hemipelvectomy.
Three patients died on the hospital ward (patients are
marked with a † in the column “Case” in Tables 2 and
3). One patient died of mass bleeding and coagulopathy
on the day of operation; two patients died due to com-
plications on the hospital ward 31 and 84 days after
operation.
Complications
Intraoperatively, one epidural bleeding and three injuries
of the urogenitary system occurred. The only severe com-
plication was mass bleeding and coagulopathy, occurring
in three patients.
The most common complication observed was wound
healing deficiency and infection (n = 21 (61.7%)). Surgi-
cal intervention because of infection was necessary in
eighteen patients. A mean of three surgeries was neces-
sary before secondary wound closure (range 1–11).
Vacuum-assisted closure (V.A.C.®) therapy was used in
twelve patients (66.7%). The mean duration of V.A.C.®
therapy was 50.5 days (range 10–95 days). 69% of
patients (n = 9/13) who underwent internal hemipel-
vectomy needed revision procedures compared to 43%
in the external hemipelvectomy group (n = 9/21). Five
out of seven patients underwent revision procedures in
the patient collective who received a mega-prosthetic
reconstruction after extraarticular resections. Two of
these patients developed a deep implant-associated in-
fection necessitating a second-stage external hemipel-
vectomy. All patients who underwent a second-stage
external hemipelvectomy are marked using a * in the
column “Type of Procedure” in Table 2. Conservative
treatment with antibiotics was possible in three patients
only who had undergone external hemipelvectomy.
Other procedure related complications observed on
the hospital ward in decreasing order were as follows:
deep vein thrombosis/pulmonary embolism (n = 5),
paralytic ileus/subileus (n = 2), clostridium difficile en-
terocolitis (n = 1), gall bladder hydrops (n = 1), multi-
organ failure (MOF) (n = 1) and temporary severe
disorientation/confusion in need of treatment (n = 1).
Parameters such as surgical treatment (external/in-
ternal) (p = 0.905), BMI (p = 0.677), duration of oper-
ation (p = 0.931), tumor size (p = 0.832) or radiotherapy
(p = 0.107) did not influence the onset of wound healing
disorders significantly.Oncological outcome
Resection margins were clear (R0) in 88% of patients
(n = 30). Six (17.6%) radical, eighteen (52.9%) wide and
five (14.7%) marginal resection margins were observed.
In one case the resection margin was not available.
6% (n = 2) of patients had an accidental intralesional resec-
tion (R1), one of which was treated by adjuvant radiotherapy
(high-grade chondrosarcoma) and the other by surgical re-
resection (intermediate-grade chondrosarcoma).
6% (n = 2) of patients had planned intralesional resec-
tions (R1). One patient had a R1 resection for pain relief
to ensure limb salvage in a highly palliative setting and
didn’t undergo any adjuvant therapy (intermediate-grade
chondrosarcoma with disseminated pulmonary metasta-
ses). The other patient had an intralesional resection of
a giant cell tumor of bone.
Local recurrences occurred in 8.8% of patients (n = 3)
at a mean time of 26 months after operation (range 11–
35 months). All local recurrences occurred after external
hemipelvectomies. Two local recurrences occurred in
patients who had received hemipelvectomy after primar-
ily intralesional resections (n = 1) or in recurrent disease
(n = 1). Only one local recurrence occurred in a patient
who had a primary resection after an external P1-4
hemipelvectomy.
Adjuvant radiotherapy (n = 1) in combination with intra-
lesional debulking (n = 1) was administered in two pa-
tients. One moribund patient didn’t receive any adjuvant
treatment.
Neither chemotherapy (p = 0.84) nor radiotherapy
(p = 0.378) effected the overall survival significantly.Metastasis
At the time of operation four patients had solitary pul-
monary metastases, three patients had bony metastases,
and one patient had pulmonary and lymphatic or pul-
monary, bony and soft tissue metastases each (total
number of patients with distant metastases at time of
operation n = 9 (26.5%)).
Five patients developed distant metastases after a mean
of 13 months after operation (range 3–41 months). Pul-
monary metastases occurred in four patients, bony metas-
tases in one patient. Four patients died after a mean time
of 4 months (range 0–8.5 months). One patient (high-
grade osteosarcoma) achieved a complete remission with
adjuvant chemotherapy and currently shows no evidence
of disease (at 64 months after operation).Survival
At a current follow-up of a mean of 56 months (range 7 –
166 months) 35.5% (n = 11/31) of patients are alive with
no evidence of disease (NED). 64.5% of patients died of
disease (n = 14/31; 45.2%) or other causes (n = 6/31;
Guder et al. BMC Musculoskeletal Disorders  (2015) 16:33 Page 7 of 919.3%) at a mean time of 22 months after operation (range
0–95 months).
According to Kaplan-Meier analysis, we found that pallia-
tive patients (n = 9) who presented with distant metastases
at the time of operation had an estimated mean survival of
26 months (std. error 10.558; CI: 4.89-46.28) after operation
compared to 61 months (std. error 15. 276; CI: 31.06-90.94)
in patients (n = 25) who didn’t have metastases and were
treated with a curative intent. Interestingly, there was no sta-
tistically significant influence of the event metastasis at time
of operation versus no metastasis at time of operation on
the overall survival (p = 0.119). However, all but one patient
presenting with metastases at time of operation died of dis-
ease after an average of 22 months (range 0–82 months).
The one surviving patient (Pat. 31, Tables 2 and 3) had a
solitary bony metastasis of thyroid gland carcinoma and is
free of disease at last follow up 19 months after operation.
Patients without metastases at the time of operation died of
disease after an average of 37 months after operation
(Figure 1).
Significant influencing factors on survival were tumor
size larger than 10 cm (p > 0.058) and the event local re-
lapse (p = 0.027).
Functional outcome
In eleven surviving patients, the functional outcome after
operation was evaluated. After internal hemipelvectomy
one patient walks freely without aids, another one uses a
cane; three patients are reliant on crutches for short and a
wheelchair for long distances. After external hemipelvect-
omy two patients are wheelchair-bound; one of them canFigure 1 Cumulative survival of patients (n = 9) with metastases at tim
at time of operation.only use it for short periods at a time and two patients rely
on crutches for short and a wheelchair for longer dis-
tances. Two patients were lost to functional follow-up.
Discussion
The results presented in this study emphasize that both
internal and external hemipelvectomy are possible in
elderly patients with a curative and palliative intention.
In this study, duration of operation was an average of
five hours for internal and 3 hours for external hemipel-
vectomy. The perioperative blood transfusion rate varies
greatly depending on type and extent of procedure per-
formed. These findings are comparable with the results
presented by Grimer et al. and Senchenkov et al. [5,9].
They report a mean blood loss of two liters up to an aver-
age use of 13.4 units. There is a wide range regarding
published operation times though our results are in ac-
cordance with the operating times published by Grimer
et al. [9].
However, we observed an increased overall surgical
risk and a higher perioperative complication rate in this
study population compared to younger patient collec-
tives. In this series, we found an observed hospital mor-
tality of 8.8% (n = 3). Other series report a mortality rate
ranging from 0% to 5% [2,4,5,9]. Mass bleeding with
consecutive coagulopathy and multi-organ failure has
been observed as a cause and is in accordance with the
findings in this study [5]. The slightly elevated mortality
rate in this study might be accredited to comorbidities
and inferior physical coping mechanisms in elderly com-
pared to younger patients.e of operation compared to patients (n = 25) without metastases
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cluded urogenitary injuries (n = 3; 8.8%) and are also men-
tioned with a frequency of 18% by Senchenkov et al. [5].
Further, Senchenkov et al. [5] also report a correlation of
operative time and hemipelvectomy extent as predictive
factors of postoperative wound infection and flap necrosis.
Compared to infection rates reported in recent literature
(13 - 45%) our findings of 61.7% are elevated [4,5,7,9,14].
Hillmann et al. [14] published 50% of infections in patients
who underwent prosthetic and allograft reconstruction or a
combination of both, signifying a higher risk of infection in
the presence of foreign material bodies in the wound cavity.
In this study, nine of thirteen patients (69.2%) who under-
went internal hemipelvectomy needed surgical wound revi-
sions for infection, leading to external hemipelvectomy in
two extraarticular (mega prosthesis reconstruction) and
one supraacetabular resection (8.8%; n = 3). Reports of
second-stage external hemipelvectomies for infection after
a limb salvage approach have been reported in other series
and compare with our findings [14]. Of twenty-one external
hemipelvectomies in this study, twelve patients (57.1%)
developed wound-healing disorders necessitating surgical
approaches in nine patients (42.9%). Considering that oper-
ation time in this study is relatively short compared to the
range published by Senchenkov et al. [5] other factors that
might have caused higher infection rates among our pa-
tients have to be considered. Other reported predicting fac-
tors for wound infection such as age, immunosuppression,
obesity, malnutrition, diabetes, anemia, radiation and dur-
ation of operation [5] - among others - indicate that the
cause for the elevated infection rate in this study is most
probably multifactorial in elderly patients, considering the
fact that 47% suffered of at least one significant comorbidity
in this study.
Additionally, the tumor size in this study (81.8% ≥ 10 cm)
exceeds reported sizes in other collectives (35%-77.6%
≥10 cm) and might have caused both a higher rate of abla-
tive procedures performed and wound infections [3,4,8,15].
With regard to the oncological outcome no parameter
in disfavor of hemipelvectomy in patients over 65 years
was found. Overall local recurrence occurred in three pa-
tients (8.8%), two of which had received a hemipelvectomy
for persistent or recurrent disease. Other studies report
similar and higher local recurrence rates (6-50%), indicat-
ing that hemipelvectomy in elderly patients and large tu-
mors works as effectively for local control as it does in
other collectives [2-4,7,15,16].
An overall survival of 35.5% at a current follow-up of 56
months presented in this study is comparable with other
findings in literature (27%-45% at five years) [3,9,15]. The
poor prognosis observed for pelvic high-grade sarcomas in
literature reflects in these results as well [3,4,15,16]. Inter-
estingly, even patients with pulmonary metastases at the
time of operation presented a mean survival period of 22months from operation to DOD (Dead of Disease). There-
fore, we believe that for reasons of local control, pain relief
and preservation of quality-of-life for a period of time
close to two years, performing hemipelvectomy seems jus-
tified even in palliative situations.
Since most elderly patients who underwent hemipelvect-
omy in this study are permanently disabled regardless of
the procedure performed, one has to carefully balance the
advantage of preserving the patients’ physical integrity
performing an internal hemipelvectomy with the disad-
vantages of this procedure (higher risk of complications/
wound infections with secondary amputations/longer hos-
pital stay) compared to an external hemipelvectomy espe-
cially in palliative situations. Grimer et al. [9] presented
good overall results for patients with external hemipelvect-
omy treated with a palliative intent in terms of pain relief,
improved mobilization and preservation of as much
quality-of-life as possible as major goals. This study shows
that external hemipelvectomy is superior to internal hemi-
pelvectomy in terms of shorter hospitalization periods and
fewer severe complications in elderly patients. Further, as
Grimer et al. [9] reported we have also made promising ex-
periences using vacuum-assisted closure devices in wound-
healing deficiencies. We also continue to do V.A.C.® therapy
in an outpatient clinic setting, thus reducing hospitalization
periods and enabling the patients to spend more time in
their domestic environment.
With regard to our results, we consider external hemi-
pelvectomy as a feasible treatment option in elderly pa-
tients more often than in younger patient collective.
Conclusions
Little information analyzing the surgical and oncological
outcome in patients undergoing hemipelvectomy at 65 years
of age or older is available in literature. We are aware of the
limited validity of our results due to a small number of in-
cluded cases and retrospective study design. But the findings
of this case series suggest the feasibility of internal and exter-
nal hemipelvectomy in elderly patients and in light of the
demographic aging of our society, as well as improved onco-
logical treatment options, we believe this issue is becoming
more and more important and our results can offer a basis
for the difficult treatment decisions in these patients.
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